Table 1.
Patient and tumour characteristics
| All patients N = 561 |
BCS N = 362 (64.5%) |
Mastectomy N = 199 (35.5%) |
p value | |
|---|---|---|---|---|
| Age mean (range) | 50.42 (23–81) | 50.65 (24–81) | 49.99 (23–74) | .481 |
| Clinical tumour status (pre-NAC) | < .001 | |||
| T1 | 70 (12.5) | 54 (14.9) | 16 (8.0) | |
| T2 | 330 (58.8) | 249 (68.8) | 81 (40.7) | |
| T3 | 135 (24.1) | 53 (14.6) | 82 (41.2) | |
| T4 | 26 (4.6) | 6 (1.7) | 20 (10.1) | |
| Clinical node status (pre-NAC) | < .001 | |||
| Negative | 302 (53.8) | 219 (60.5) | 83 (41.7) | |
| Positive | 259 (46.2) | 143 (39.5) | 116 (58.3) | |
| Histology | ||||
| Ductal | 439 (78.3) | 298 (82.3) | 141 (70.9) | < .001 |
| Lobular | 65 (11.6) | 26 (7.2) | 39 (19.6) | |
| Other | 57 (10.2) | 38 (10.5) | 19 (9.5) | |
| Subtype | .589 | |||
| HRposHER2neg | 323 (57.6) | 208 (57.5) | 115 (57.8) | |
| HRposHER2pos | 102 (18.2) | 61 (16.9) | 41 (20.6) | |
| HRnegHER2pos | 46 (8.2) | 32 (8.8) | 14 (7.0) | |
| Triple negative | 90 (16.0) | 61 (16.9) | 29 (14.6) | |
| Grade | .635 | |||
| I | 118 (21.0) | 74 (20.4) | 44 (22.1) | |
| II | 192 (34.2) | 125 (34.5) | 67 (33.7) | |
| III | 157 (28.0) | 107 (29.6) | 50 (25.1) | |
| Unknown | 94 (16.8) | 56 (15.5) | 38 (19.1) | |
| Multifocal or multicentric | < .001 | |||
| No | 389 (69.3) | 297 (82.0) | 92 (46.2) | |
| Yes | 172 (30.7) | 65 (18.0) | 107 (53.8) | |
| Breast pCR (ypT0) | .077 | |||
| No | 430 (76.6) | 269 (74.3) | 161 (80.9) | |
| Yes | 131 (23.4) | 93 (25.7) | 38 (19.1) | |
| Axillary pCR (ypN0) | < .001 | |||
| No | 170 (30.3) | 77 (21.3) | 93 (46.7) | |
| Yes | 385 (68.6) | 282 (77.9) | 103 (51.8) | |
| Unknowna | 6 (1.1) | 3 (0.8) | 3 (1.5) | |
| Endocrine therapy | .273 | |||
| No | 145 (25.8) | 99 (27.3) | 46 (23.1) | |
| Yes | 416 (74.2) | 263 (72.2) | 153 (76.9) | |
| Targeted therapy | .407 | |||
| No | 412 (73.4) | 270 (74.6) | 142 (71.4) | |
| Yes | 149b (26.6) | 92 (25.4) | 57 (28.6) |
Values are numbers (%) unless stated otherwise
HRposHER2neg hormone receptor-positive and HER2-negative breast cacer, HRposHER2pos hormone receptor-positive and HER2-positive breast cancer, HRnegHER2pos hormone receptor-negative and HER2-positive breast cancer
a5 cN0 patients with pre-NAC SLNB positive for macrometastasis, without post-NAC axillary surgery and one cN + patient without ALND (ALND was replaced by regional radiotherapy at these patient’s request)
bOne patient was inaccurately identified as HER2-positive prior to NAC and received HER2-targeted therapy